logo

NNVC

NanoViricidesยทAMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

NNVC Profile

Nanoviricides, Inc.

A company that developing therapeutics using nanomedicine technologies to treat viral infections

Pharmaceutical
04/01/2005
09/25/2013
American Stock Exchange
7
06-30
Common stock
1 CONTROLS DRIVE, SHELTON, CONNECTICUT, 06484
--
NanoViricides, Inc., was incorporated in Nevada on April 1, 2005 and relocated to Delaware on May 30, 2023. The company is a clinical-stage company. The first drug is ready to enter the Phase II human clinical efficacy trial, and has successfully completed the Phase IA/IB human clinical safety and tolerability trials. They also have several additional drug candidates in various stages of preclinical development, including IND application stage and late-stage IND-supported non-clinical studies.